创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

郭斌生, 陆继强, 欧瑜, 徐寒梅. 骨关节炎药物治疗研究进展[J]. 药学进展, 2018, 42(9): 697-703.
引用本文: 郭斌生, 陆继强, 欧瑜, 徐寒梅. 骨关节炎药物治疗研究进展[J]. 药学进展, 2018, 42(9): 697-703.
GUO Binsheng, LU Jiqiang, OU Yu, XU Hanmei. Advances in Research on Pharmacotherapy of Osteoarthritis[J]. Progress in Pharmaceutical Sciences, 2018, 42(9): 697-703.
Citation: GUO Binsheng, LU Jiqiang, OU Yu, XU Hanmei. Advances in Research on Pharmacotherapy of Osteoarthritis[J]. Progress in Pharmaceutical Sciences, 2018, 42(9): 697-703.

骨关节炎药物治疗研究进展

Advances in Research on Pharmacotherapy of Osteoarthritis

  • 摘要: 骨关节炎是临床上常见的退行性关节疾病之一,能引起患者关节疼痛及机体运动功能障碍,并且是老年人残疾的主要原因。由于骨关节炎的发病机制尚不明确,且关节软骨的自愈能力差,该病治疗选择有限。目前,传统的药物治疗仍是最常用的骨关节炎治疗选择,主要用于缓解疼痛和抗炎,仅能控制症状,且不良反应高发。更有效的、副作用更少的新型骨关节炎治疗药物的研发正在进行中,其中一些药物已经上市或正处于临床研究阶段。对骨关节炎药物治疗研究进展进行综述。

     

    Abstract: As a degenerative joint disorder commonly encountered in clinical practice, osteoarthritis (OA) causes joint pain and motor dysfunction in patients, and is the leading cause of disability in elderly people. Due to the poor self-healing capacity of articular cartilage and the unclear etiopathogenesis of OA, treatments options are still very limited. Traditional pharmaceutical therapy aiming at pain relief and anti-inflammation is still the most common treatment option for OA although it can only control the symptoms with high incidence of adverse effects. Studies of new OA drugs with increased effectiveness and less side effects are underway, with some of these drugs entering the market or clinical trials. In this article, the advances in research on pharmacotherapy of osteoarthritis were reviewed.

     

/

返回文章
返回